Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
Date
2020Author
Buijsers, Baranca
Yanginlar, Cansu
Maciej-Hulme, Marissa L.
Mast, Quirijn de
Vlag, Johan van der
Metadata
Show full item record
Documentos PDF
Abstract
Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney.
Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality
in COVID-19. In part, this beneficial effect could be explained by the anticoagulant properties of heparin/
LMWH. Here, we summarise potential beneficial, non-anticoagulant mechanisms underlying treatment of
COVID-19 patients with heparin/LMWH, which include: (i) Inhibition of heparanase activity, responsible for
endothelial leakage; (ii) Neutralisation of chemokines, and cytokines; (iii) Interference with leukocyte trafficking; (iv) Reducing viral cellular entry, and (v) Neutralisation of extracellular cytotoxic histones. Considering the multiple inflammatory and pathogenic mechanisms targeted by heparin/LMWH, it is warranted to
conduct clinical studies that evaluate therapeutic doses of heparin/LMWH in COVID-19 patients. In addition,
identification of specific heparin-derived sequences that are functional in targeting non-anticoagulant mechanisms may have even higher therapeutic potential for COVID-19 patients, and patients suffering from other
inflammatory diseases.
Link to resource
https://doi.org/10.1016/j.ebiom.2020.102969Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.